News From The Biomaterials & Medical Product Commercialization (BMPC) SIG

摘要

Commercializing a new biomaterial or medical product goes well beyond the scientific research and development that occurs on the lab bench in an academic setting. Academicians and new entrepreneurs in this space encounter a number of additional challenges unique to medical devices and pharmaceuticals, including, but not limited to, regulatory approval, clinical trials, intellectual property protection, patent costs, litigation, manufacturing scale up, and marketing. The Biomaterials & Medical Product Commercialization (BMPC) Special Interest Group (SIG) serves as a forum to promote translation and commercialization of novel technologies arising from academic labs. SIG members interact and exchange information on these and related issues, providing a forum to assist Society For Biomaterials (SFB) members in preparing for and dealing with the commercialization of products. We currently have 282 members in our SIG, many of whom actively participate in the SFB Annual Meeting as session organizers, session chairs, and abstract reviewers, as well as oral talk and poster presenters. BMPC SIG members represent a broad spectrum of professionals from academia, small businesses, large corporations, and government organizations. We are striving to increase participation in this SIG, and to also organize more workshops and sessions dealing with commercialization for biomaterials and medical devices.